Insider · CIK 0001819612
Kevin P Grahmann
officer
Files at KMI (KINDER MORGAN, INC.). First filing Sep 16, 2025, latest Sep 16, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $659k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
KMI: KINDER MORGAN, INC.
KMIOct 9, 2026 · close 32.49
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 53Moderate | KINDER MORGAN, INC. | $659k 23,867 shares | -29% | +33% from low-10% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2025 | KMI KINDER MORGAN, INC. | SOpen-market sale Class P Common Stock | -23,867 | $27.61 | $659k | 58,653 | Sep 16, 2025 |
| Jul 31, 2025 | KMI KINDER MORGAN, INC. | MOption exercise Class P Common Stock | +34,663 | $0.00 | $0 | 93,316 | Aug 4, 2025 |
| Jul 31, 2025 | KMI KINDER MORGAN, INC. | FTax withholding Class P Common Stock | -10,796 | $28.06 | $303k | 82,520 | Aug 4, 2025 |
| Jul 31, 2025 | KMI KINDER MORGAN, INC. | MOption exercise Restricted Stock Unitderivative | -34,663 | $0.00 | $0 | 0 | Aug 4, 2025 |
| Jul 15, 2025 | KMI KINDER MORGAN, INC. | AGrant or award Restricted Stock Unitderivative | +32,212 | $0.00 | $0 | 32,212 | Jul 17, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.